logo
  

Galmed: New Data Reinforces Expansion Of Aramchol's Clinical Development To Additional Indications

Galmed Pharmaceuticals Ltd. (GLMD) reported results showing significant effects of Aramchol in pre-clinical model of both lung and gastrointestinal fibrosis. The company said treatment with Aramchol resulted in statistically significant fibrosis improvement in a validated bleomycin model of lung fibrosis, comparable to Pirfenidone which is the gold standard treatment. Statistically significant improvements were also noticed in a validated DSS model of inflammatory bowel disease.

"I am excited with today's news showing that established data about the role of SCD1 in lipid metabolism and fibrosis in the liver, is being replicated in other organs," said Allen Baharaff, CEO of Galmed.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Stocks staged a significant recovery attempt after pulling back sharply in early trading on Wednesday but still ended the day modestly lower. The major averages gave back ground after moving sharply higher over the two previous sessions. Three scientists have shared the Nobel Prize for Chemistry for their work that led to the development of linking molecules together, known as click chemistry, and bioorthogonal chemistry. Morten Meldal and K. Barry Sharpless have laid the foundation for a functional form of chemistry - click chemistry - in which molecular building blocks snap together quickly and efficiently. Carolyn R. Bertozzi The Institute for Supply Management released a report on Wednesday showing a modest slowdown in the pace of growth in U.S. service sector activity in the month of September. The ISM said its services PMI edged down to 56.7 in September from 56.9 in August, although a reading above 50 still indicates growth in the sector.
RELATED NEWS
Follow RTT